NICE TA199 (August 2010) Enbrel/Remicade/Humira: Etanercept, infliximab and adalimumab
NICE TA220 (April 2011) Simponi: Golimumab
Supplementary to the written TA guidance, NICE publish a commissiong algorithm which is a tool to aid the implementation of the guidance. In simple terms an 'at a glance' flow chart.
Here is the current document for PsA.
266-NICEPsA.pdf (487 KB)NICE TA 340 (rapid review of TA 313 May 2014) (June 2015) Stelara: Ustekinumab
NICE ADVICE ESNM42 (June 2014) Cimzia: Certolizumab pegol
In development:
Otezla (expected October 2015): Apremilast
Rumoured to be in the pipeline:
Cosentyx: Secukinumab